Step Pharma is developing novel therapeutics that inhibit the enzyme CTP Synthase 1 (CTPS1). Our most advanced programme is STP938 which is being developed as a targeted therapy for T-cell malignancies.
Step Pharma was created on the basis of research on genetic immunodeficiencies led by Prof. Alain Fischer at the Imagine Institute (Paris, France) which established the essential role of CTPS1 in T- and B-cell proliferation. The company has developed a series of potent, selective, orally available small molecular weight inhibitors of CTPS1 with STP938 expected to enter clinical development in 2021. The role of CTPS1 in modulating lymphocytes has been genetically validated and the company has shown in preclinical experiments the potential for CTPS1 inhibitors to reduce disease severity in models of autoimmune disease and inhibit T- and B-cell proliferation in models of cancer.
Step Pharma continues to work closely with the scientific founders Prof Alain Fischer and Prof Sylvain Latour benefiting from their extensive experience in immunology. In addition Step Pharma has a strong management team and a committed investor group.
For more information, please contact:
Phone +45 2481 6967